Page 8 - Daptorum Group News Today

Published: Apr 22, 2021 By Brandon May Clinical-stage biopharmaceutical company, Aptorum Group Limited, announced today that it has entered into a material transfer and option agreement with Yale Universityto study preclinical stage novel immunomodulators targeting autoimmune and oncology diseases. Aptorum Group’s stock is  reportedly up 6% premarket following the announcement of the material transfer and option agreement with Yale. Specifically, the novel immunomodulators under in...

Aptorum Group Limited Reports 2020 Fiscal Year End Financial Results and Provides Business Update Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced financial results for the fiscal year ended December 31, 2020, and provided an update on clinical and corporate developments. Mr. Darren Lui, President and Executive Director of Aptorum Group Limited, comme...

(1) Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada (Health Canada) regarding the Clinical Trial Application (CTA) to commence a Phase 1 study of ALS-4, an orally administered small molecule dr...

Aptorum Group Limited (NASDAQ: APM) receives clearance from the Public Health Agency of Canada in regards to its Clinical Trial Application to begin Phase 1 study of ALS-4, its orally taken small molecule drug that is intended to treat infections that are caused by Staphylococcus aureus that includes MRSA. Dr. Clark Cheng, Chief Medical Officer... Aptorum Group Limited (NASDAQ: APM) receives clearance from the Public Health Agency of Canada in regards to its Clinical Trial Application to begin P...

Aptorum Group announces submission of Clinical Trial Application 22nd December 2020     Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical conditions including infectious diseases, announced that the company, through its wholly owned subsidiary Aptorum International Limited, has submitted a Clinical Trial Application (CTA) with the Public Health Ag...

Aptorum Group Limited Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) Tuesday, December 22, 2020 8:35PM IST (3:05PM GMT)   Regulatory News:   Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for ...

December 22, 2020 healthcare Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a varie...

Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders Regulatory News: Aptorum Group Limited (Nasdaq: APM; Euronext Paris: APM) (the "Company", "Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, today announced the results of its 2020 annual general meeting of shareholders, which was held on December 9, 2020, in Hong Kong. At the annual general meeting, the required number of s...